Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.
Evgen Pharma is a publicly quoted company. It joined the AIM market of the London Stock Exchange in October 2015 and its shares trade under the ticker symbol EVG.Find out more
Our clinical pipeline is based on our proprietary Sulforadex® platform technology. Phase I studies have been successfully completed and we are progressing two clinical programmes into Phase II. The two programmes – targeting breast cancer and subarachnoid haemorrhage – benefit from the substantial body of data generated by academic research into sulforaphane.
The Sulforadex® stabilisation technology means that sulforaphane, and related analogues, can be delivered as a stable active in an oral pharmaceutical product.Find out more